CONSHOHOCKEN, Pa., May 8, 2025 /PRNewswire/ -- The GBS | CIDP Foundation International is commemorating Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy Awareness Month ...
The GBS|CIDP Foundation International is thrilled to announce the publication of shared key terms to describe the management of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the esteemed ...
CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and ...
The US Food and Drug Administration (FDA) has approved Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HyQvia, Takeda) as maintenance therapy to prevent relapse of ...
The present patient showed characteristic features of GBS in the acute phase with rapid progression of symptoms over several days. She partially recovered within 2–4 months of initial treatment, ...
Please provide your email address to receive an email when new articles are posted on . Reasons for misdiagnosis or delayed diagnosis for CIDP are complex and include multiple factors. The FDA ...
Everyday Health on MSN
How pain is managed in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Learn how pain is managed in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), including medications, therapies, procedures, and lifestyle strategies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results